HAEM5:In situ mantle cell neoplasm: Difference between revisions
| [checked revision] | [checked revision] |
Bailey.Glen (talk | contribs) |
Bailey.Glen (talk | contribs) No edit summary |
||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
{{Under Construction}} | {{Under Construction}} | ||
<blockquote class= | <blockquote class="blockedit">{{Box-round|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:In Situ Mantle Cell Neoplasia]]. | ||
}}</blockquote> | }}</blockquote> | ||
| Line 12: | Line 12: | ||
Rina Kansal, MD; Versiti Blood Center of Wisconsin | Rina Kansal, MD; Versiti Blood Center of Wisconsin | ||
==WHO Classification of Disease== | ==WHO Classification of Disease== | ||
| Line 36: | Line 33: | ||
|In situ mantle cell neoplasm | |In situ mantle cell neoplasm | ||
|} | |} | ||
==Related Terminology== | |||
== | |||
{| class="wikitable" | {| class="wikitable" | ||
|+ | |+ | ||
|Acceptable | |Acceptable | ||
| | |In situ mantle cell neoplasia | ||
|- | |- | ||
|Not Recommended | |Not Recommended | ||
| | |In situ mantle cell lymphoma; mantle cell lymphoma–like B cells of uncertain/undetermined significance | ||
|} | |} | ||
| Line 496: | Line 127: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Chr #!! | !Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s) | ||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||
| Line 599: | Line 230: | ||
!Chromosomal Pattern | !Chromosomal Pattern | ||
!Molecular Pathogenesis | !Molecular Pathogenesis | ||
! | !Prevalence - | ||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
! | !Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | ||
! | !Established Clinical Significance Per Guidelines - Yes or No (Source) | ||
! | !Clinical Relevance Details/Other Notes | ||
|- | |- | ||
|<span class="blue-text">EXAMPLE:</span> | |<span class="blue-text">EXAMPLE:</span> | ||
| Line 629: | Line 260: | ||
|} | |} | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV/INDEL)== | ||
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span> | |||
{| class="wikitable sortable" | |||
|- | |||
!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence - | |||
Common >20%, Recurrent 5-20% or Rare <5% (Disease) | |||
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T | |||
!Established Clinical Significance Per Guidelines - Yes or No (Source) | |||
!Clinical Relevance Details/Other Notes | |||
|- | |||
|<span class="blue-text">EXAMPLE:</span>''EGFR'' | |||
<br /> | |||
|<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations | |||
|<span class="blue-text">EXAMPLE:</span> Oncogene | |||
|<span class="blue-text">EXAMPLE:</span> Common (lung cancer) | |||
|<span class="blue-text">EXAMPLE:</span> T | |||
|<span class="blue-text">EXAMPLE:</span> Yes (NCCN) | |||
|<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references). | |||
|- | |||
|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations | |||
<br /> | |||
|<span class="blue-text">EXAMPLE:</span> Variable LOF mutations | |||
|<span class="blue-text">EXAMPLE:</span> Tumor Supressor Gene | |||
|<span class="blue-text">EXAMPLE:</span> Common (breast cancer) | |||
|<span class="blue-text">EXAMPLE:</span> P | |||
| | |||
|<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer. | |||
|- | |||
|<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations | |||
|<span class="blue-text">EXAMPLE:</span> Activating mutations | |||
|<span class="blue-text">EXAMPLE:</span> Oncogene | |||
|<span class="blue-text">EXAMPLE:</span> Common (melanoma) | |||
|<span class="blue-text">EXAMPLE:</span> T | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content. | |||
There are numerous publications for gene mutations in overt mantle cell lymphoma. A recent systematic meta-analysis of 32 studies published during 2006 to 2019, excluding review articles, detailed the findings for gene mutations in mantle cell lymphoma by analyzing 2127 individual overt mantle cell lymphoma patients and 2173 samples that were included in the analyzed studies.<ref name=":10">{{Cite journal|last=Hill|first=Holly A.|last2=Qi|first2=Xinyue|last3=Jain|first3=Preetesh|last4=Nomie|first4=Krystle|last5=Wang|first5=Yucai|last6=Zhou|first6=Shouhao|last7=Wang|first7=Michael L.|date=2020-07-14|title=Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis|url=https://pubmed.ncbi.nlm.nih.gov/32598477|journal=Blood Advances|volume=4|issue=13|pages=2927–2938|doi=10.1182/bloodadvances.2019001350|issn=2473-9537|pmc=7362354|pmid=32598477}}</ref> These studies included the nodal and the leukemic forms of overt mantle cell lymphoma. As per this meta-analysis, in overt mantle cell lymphoma tumor or bone marrow samples at diagnosis or baseline, the most frequent genetic abnormalities occurred in the ''ATM'' (43.5%), ''TP53'' (26.8%), ''CDKN2A'' (23.9%), ''CCND1'' (20.2%), ''NSD2'' (15.0%), ''KMT2A'' (8.9%), ''S1PR1'' (8.6%), and ''CARD11'' (8.5%) genes.<ref name=":10" /> Aberrations in ''IGH'' (38.4%) and ''MYC'' (20.8%) were detected primarily through cytogenetic methods, also in those same tumor specimens.<ref name=":10" /> | There are numerous publications for gene mutations in overt mantle cell lymphoma. A recent systematic meta-analysis of 32 studies published during 2006 to 2019, excluding review articles, detailed the findings for gene mutations in mantle cell lymphoma by analyzing 2127 individual overt mantle cell lymphoma patients and 2173 samples that were included in the analyzed studies.<ref name=":10">{{Cite journal|last=Hill|first=Holly A.|last2=Qi|first2=Xinyue|last3=Jain|first3=Preetesh|last4=Nomie|first4=Krystle|last5=Wang|first5=Yucai|last6=Zhou|first6=Shouhao|last7=Wang|first7=Michael L.|date=2020-07-14|title=Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis|url=https://pubmed.ncbi.nlm.nih.gov/32598477|journal=Blood Advances|volume=4|issue=13|pages=2927–2938|doi=10.1182/bloodadvances.2019001350|issn=2473-9537|pmc=7362354|pmid=32598477}}</ref> These studies included the nodal and the leukemic forms of overt mantle cell lymphoma. As per this meta-analysis, in overt mantle cell lymphoma tumor or bone marrow samples at diagnosis or baseline, the most frequent genetic abnormalities occurred in the ''ATM'' (43.5%), ''TP53'' (26.8%), ''CDKN2A'' (23.9%), ''CCND1'' (20.2%), ''NSD2'' (15.0%), ''KMT2A'' (8.9%), ''S1PR1'' (8.6%), and ''CARD11'' (8.5%) genes.<ref name=":10" /> Aberrations in ''IGH'' (38.4%) and ''MYC'' (20.8%) were detected primarily through cytogenetic methods, also in those same tumor specimens.<ref name=":10" /> | ||
| Line 636: | Line 311: | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
|- | |- | ||
!Gene; Genetic Alteration!! | !Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations | ||
! | !Diagnostic Significance (Yes, No or Unknown) | ||
!Prognostic Significance (Yes, No or Unknown) | !Prognostic Significance (Yes, No or Unknown) | ||
!Therapeutic Significance (Yes, No or Unknown) | !Therapeutic Significance (Yes, No or Unknown) | ||
| Line 692: | Line 367: | ||
Fluorescence ''in situ'' hybridization (FISH) for the t(11;14) translocation is the most commonly used method, in conjunction with immunohistochemistry for the overexpression of cyclin D1 in the neoplastic mantle cells. Both FISH and immunohistochemistry may be performed on paraffin-embedded tissue sections to allow identification of the abnormalities within specific cells (neoplastic) in the histologic sections. | Fluorescence ''in situ'' hybridization (FISH) for the t(11;14) translocation is the most commonly used method, in conjunction with immunohistochemistry for the overexpression of cyclin D1 in the neoplastic mantle cells. Both FISH and immunohistochemistry may be performed on paraffin-embedded tissue sections to allow identification of the abnormalities within specific cells (neoplastic) in the histologic sections. | ||
Conventional cytogenetics performed on involved lymphoid tissues is also used by some laboratories.<ref name=":4" /> | Conventional cytogenetics performed on involved lymphoid tissues is also used by some laboratories.<ref name=":4">{{Cite journal|last=Espinet|first=Blanca|last2=Solé|first2=Francesc|last3=Pedro|first3=Carme|last4=Garcia|first4=Mar|last5=Bellosillo|first5=Beatriz|last6=Salido|first6=Marta|last7=Florensa|first7=Lourdes|last8=Camacho|first8=Francisca I.|last9=Baró|first9=Teresa|date=2005-11|title=Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?|url=https://pubmed.ncbi.nlm.nih.gov/16260278|journal=Human Pathology|volume=36|issue=11|pages=1232–1237|doi=10.1016/j.humpath.2005.08.021|issn=0046-8177|pmid=16260278}}</ref> | ||
==Familial Forms== | ==Familial Forms== | ||
| Line 709: | Line 384: | ||
==Additional Information== | ==Additional Information== | ||
This disease is <u>defined/characterized</u> as detailed below: | |||
*The Latin phrase “in situ” means “in the natural or original position or place”, as per the Merriam-Webster dictionary. In normal benign lymphoid tissues, the mantle zones of lymphoid follicles are formed by naïve mature B-cells after maturation from precursor B-cells in the bone marrow. In situ mantle cell neoplasm is a pre-malignant neoplasm composed of mantle cells “in their natural position” that harbor, in addition, the t(11;14) balanced translocation characteristic of mantle cell lymphoma with the overexpression of cyclin D1 protein. | |||
*An in situ mantle cell neoplasm may precede, co-exist with, or may occur after the development of an overt mantle cell lymphoma. This pre-malignant neoplasm is more often identified in patients newly diagnosed with an overt mantle cell lymphoma in whom a retrospective examination of a prior reactive-appearing lymph node or lymphoid tissue biopsy shows the presence of in situ mantle cell neoplasm. In situ mantle cell neoplasm is only rarely diagnosed in lymph nodes diagnosed as benign or reactive lymphoid hyperplasia after biopsy for enlargement or other symptomatic causes. The diagnostic criteria for in situ mantle cell neoplasm are currently based primarily on histopathologic examination (description in the morphologic features section). The pathologic diagnosis of in situ mantle cell neoplasm requires distinguishing from two major disease entities: (1) reactive lymphoid hyperplasia, and (2) mantle cell lymphoma with a mantle zone pattern. Of note, in situ mantle cell neoplasm may co-exist with any overt mature B-cell lymphoma, including as a component of a composite lymphoma. | |||
*Synonyms/terminology - In situ mantle cell neoplasia, term used in the revised 4<sup>th</sup> edition World Health Organization classification<ref>Swerdlow SH, et al., (2017). Mantle cell lymphoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p290.</ref> and in the International Consensus Classification of mature lymphoid neoplasms<ref>{{Cite journal|last=Campo|first=Elias|last2=Jaffe|first2=Elaine S.|last3=Cook|first3=James R.|last4=Quintanilla-Martinez|first4=Leticia|last5=Swerdlow|first5=Steven H.|last6=Anderson|first6=Kenneth C.|last7=Brousset|first7=Pierre|last8=Cerroni|first8=Lorenzo|last9=de Leval|first9=Laurence|date=2022-06-02|title=The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee|url=https://pubmed.ncbi.nlm.nih.gov/35653592|journal=Blood|pages=blood.2022015851|doi=10.1182/blood.2022015851|issn=1528-0020|pmid=35653592}}</ref>; in situ mantle cell lymphoma (historical); mantle cell lymphoma in situ (historical); mantle cell lymphoma (MCL)-like B-cells of undetermined significance<ref>{{Cite journal|last=Fend|first=Falko|last2=Cabecadas|first2=José|last3=Gaulard|first3=Philippe|last4=Jaffe|first4=Elaine S.|last5=Kluin|first5=Philip|last6=Kuzu|first6=Isinsu|last7=Peterson|first7=Loann|last8=Wotherspoon|first8=Andrew|last9=Sundström|first9=Christer|date=2012-09|title=Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden|url=https://pubmed.ncbi.nlm.nih.gov/24307917|journal=Journal of Hematopathology|volume=5|issue=3|doi=10.1007/s12308-012-0148-6|issn=1868-9256|pmc=3845020|pmid=24307917}}</ref> (historical) | |||
[[File:Schematic_showing_two_main_routes_for_the_development_of_overt_mantle_cell_lymphoma_from_an_in_situ_mantle_cell_neoplasm.jpg|alt=|none|thumb]]The <u>epidemiology/prevalence</u> of this disease is detailed below: | |||
*The real prevalence of in situ mantle cell neoplasm is currently unknown. The published literature for in situ mantle cell neoplasm is limited primarily to case reports, including collectively studied cases,<ref name=":0">{{Cite journal|last=Carvajal-Cuenca|first=Alejandra|last2=Sua|first2=Luz F.|last3=Silva|first3=Nhora M.|last4=Pittaluga|first4=Stefania|last5=Royo|first5=Cristina|last6=Song|first6=Joo Y.|last7=Sargent|first7=Rachel L.|last8=Espinet|first8=Blanca|last9=Climent|first9=Fina|date=2012-02|title=In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior|url=https://pubmed.ncbi.nlm.nih.gov/22058203|journal=Haematologica|volume=97|issue=2|pages=270–278|doi=10.3324/haematol.2011.052621|issn=1592-8721|pmc=3269489|pmid=22058203}}</ref> and retrospective studies of cases of reactive lymphoid hyperplasia,<ref name=":0" /><ref name=":1">{{Cite journal|last=Adam|first=Patrick|last2=Schiefer|first2=Ana-Iris|last3=Prill|first3=Sophie|last4=Henopp|first4=Tobias|last5=Quintanilla-Martínez|first5=Leticia|last6=Bösmüller|first6=Hans-Christian|last7=Chott|first7=Andreas|last8=Fend|first8=Falko|date=2012-12|title=Incidence of preclinical manifestations of mantle cell lymphoma and mantle cell lymphoma in situ in reactive lymphoid tissues|url=https://pubmed.ncbi.nlm.nih.gov/22790016|journal=Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc|volume=25|issue=12|pages=1629–1636|doi=10.1038/modpathol.2012.117|issn=1530-0285|pmid=22790016}}</ref> lymph nodes in specimens resected for cancer,<ref name=":2">{{Cite journal|last=Bermudez|first=Glenda|last2=González de Villambrosía|first2=Sonia|last3=Martínez-López|first3=Azahara|last4=Batlle|first4=Ana|last5=Revert-Arce|first5=José B.|last6=Cereceda Company|first6=Laura|last7=Ortega Bezanilla|first7=César|last8=Piris|first8=Miguel A.|last9=Montes-Moreno|first9=Santiago|date=2016-07|title=Incidental and Isolated Follicular Lymphoma In Situ and Mantle Cell Lymphoma In Situ Lack Clinical Significance|url=https://pubmed.ncbi.nlm.nih.gov/26945339|journal=The American Journal of Surgical Pathology|volume=40|issue=7|pages=943–949|doi=10.1097/PAS.0000000000000628|issn=1532-0979|pmid=26945339}}</ref> and lymph nodes and other organized lymphoid tissues resected for any non-hematologic cause prior to the diagnosis of overt mantle cell lymphoma<ref name=":3">{{Cite journal|last=Teixeira Mendes|first=Larissa Sena|last2=Wotherspoon|first2=Andrew|date=2016-02|title=The relationship between overt and in-situ lymphoma: a retrospective study of follicular and mantle cell lymphoma cases|url=https://pubmed.ncbi.nlm.nih.gov/26052648|journal=Histopathology|volume=68|issue=3|pages=461–463|doi=10.1111/his.12753|issn=1365-2559|pmid=26052648}}</ref>. | |||
{| class="wikitable" | |||
|+Table 1. Cohorts of tissues studied to detect in situ mantle cell neoplasm | |||
!Study cohorts for detecting in situ mantle cell neoplasm | |||
!N patients studied | |||
!In situ mantle cell neoplasm, N cases detected in the study | |||
|- | |||
|Retrospective study of cyclin D1 immunohistochemical stains in 100 consecutive cases of lymphoid hyperplasia to detect in situ mantle cell neoplasm<ref name=":0" /> | |||
|100 | |||
|0 (zero) by cyclin D1 stain<ref name=":0" /> | |||
|- | |||
|100 cases of reactive hyperplasia in lymph nodes studied by conventional cytogenetics<ref name=":4" /> | |||
|100 | |||
|0 (zero) clonal chromosomal abnormalities by conventional cytogenetics<ref name=":4" /> | |||
|- | |||
|Retrospective study of cyclin D1 immunohistochemical stains in reactive lymph nodes in surgical resection specimens of 131 consecutive patients with no history of lymphoma during a 3-month period<ref name=":1" /> | |||
|131 | |||
|0 (zero) by cyclin D1 stain<ref name=":1" /> | |||
|- | |||
|Retrospective study of lymph nodes (<u>></u> 0.5 cm size) resected with cancer in 341 consecutive patients diagnosed with colorectal (n= 201) and breast carcinoma (n= 140) during 1998-2000<ref name=":2" /> | |||
|341 | |||
|2 (0.58%) by cyclin D1 stain<ref name=":2" /> | |||
|- | |||
|Retrospective study of previous resections of lymph nodes and organized lymphoid tissues due to non-hematologic indications for surgery in 126 patients with overt mantle cell lymphoma<ref name=":3" /> | |||
|126 | |||
|2 (1.58%) by cyclin D1 stain<ref name=":3" /> | |||
|- | |||
|Retrospective study of all morphologically reactive lymph nodes and benign-appearing extranodal lymphoid infiltrates predating lymphoma diagnosis in patients diagnosed with overt mantle cell lymphoma<ref name=":1" /> | |||
|37 | |||
|0 (zero) cases reported with typical in situ mantle cell neoplasm by cyclin D1 stain;<ref name=":1" /> | |||
in 6 cases, minimal infiltration by cyclin D1 positive neoplastic mantle cells was identified at extranodal sites<ref name=":1" /> | |||
|}The <u>clinical features</u> of this disease are detailed below: | |||
* Signs and symptoms - In situ mantle cell neoplasm alone is asymptomatic and is therefore, found incidentally in lymph nodes and lymphoid tissues examined for other causes. However, since it may co-exist with an overt mantle cell lymphoma (nodal or leukemic), the signs and symptoms may vary according to the situation. The presence of B-symptoms (weight loss, fever, night sweats), fatigue, or generalized lymphadenopathy should lead to the suspicion of an overt lymphoma. | |||
* Laboratory findings - Similarly, there should be no cytopenias or lymphocytosis due to the presence of only an in situ mantle cell neoplasm. Nevertheless, small or even minute populations of light chain restricted B-cells may be detected in peripheral blood by flow cytometric immunophenotyping in the absence of increased peripheral blood lymphocyte counts. In cases of composite lymphomas, flow cytometric immunophenotypic analysis of the lymph node or lymphoid tissues may show the presence of two neoplastic B-cell populations that may prompt further or retrospective histopathologic evaluation, including for cyclin D1 immunohistochemistry on tissue sections. | |||
* The clinical features at presentation or diagnosis may depend on the situations in which the in situ mantle cell neoplasm is diagnosed, including as follows: | |||
**In a biopsy of an enlarged lymph node or extra-nodal lymphoid tissue: in biopsies performed with suspicion of a lymphoproliferative disease, in situ mantle cell neoplasm may co-exist with another mature B-cell lymphoma or with Castleman disease. Peripheral blood and/or bone marrow may be involved in addition to the histologic presence of in situ mantle cell neoplasm in lymphoid tissues. | |||
**In previous biopsies retrospectively examined after the diagnosis of an overt mantle cell lymphoma. | |||
**As an incidental finding in lymph nodes and lymphoid tissues examined for other causes, including lymph nodes in resected cancer specimens and lymphoid tissues in inflammatory conditions. | |||
* The individual patient-level table below (with the preceding summary) shows the variability in clinical features and outcome among 31 previously reported patients diagnosed histologically with an in situ mantle cell neoplasm, along with the background in which in situ mantle cell neoplasia arose in these patients. | |||
**Notably, 29% (9/31) of these in situ mantle cell neoplasm cases occurred in a background of a composite lymphoma comprised of another mature B-cell lymphoma, with follicular lymphoma (FL) being the most frequent, followed by chronic lymphocytic leukemia (CLL), and marginal zone lymphoma (nodal and extranodal types). | |||
**Among the remaining 22 patients, 31.8% (7/22), 6 males and one female, developed an overt mantle cell lymphoma after 1-20 years. This development to an overt lymphoma occurred at 2y, 4y, 4y, 4y, 10y, and 20 y after a histologically diagnosable in situ mantle cell neoplasm for the initial overt mantle cell lymphoma and after 1 year for relapsed mantle cell lymphoma. | |||
***An additional 22.7% (5/22) received chemotherapy or radiotherapy for lymphoma. | |||
***An additional 9% (2/22) patients, both women, had leukemic involvement by mantle cell lymphoma and were alive with disease at long-term follow-up of 12 y and 19.5 y. | |||
***One additional patient (1/22, 4.5%) died at 1.3 y. | |||
***27% (6/22) patients did not develop overt lymphoma at 0.08y, 0.66 y, 1 y, 3y, 5y, and 16 y follow-up. | |||
***Follow-up not available for one (1/22) patient. | |||
{| class="wikitable" | |||
|+ | |||
Table 2. Clinical features for 31 individual patients with a histologic diagnosis of in situ mantle cell neoplasm | |||
! colspan="2" |Characteristics of reported patients and clinical situations for in situ mantle cell neoplasm diagnosis | |||
!Outcome after in situ mantle cell neoplasm diagnosis; follow-up time in years (y) | |||
!Composite lymphoma | |||
!Tissues with in situ mantle cell neoplasm | |||
|- | |||
! colspan="5" |'''7 patients with in situ mantle cell neoplasm diagnosed with SOX11 positive neoplastic mantle cells<ref name=":0" />''' | |||
|- | |||
| colspan="3" |'''43% (3 of 7) patients, all males, developed overt mantle cell lymphoma''' | |||
| | |||
| | |||
|- | |||
|N=1 | |||
|Male aged 70 y with bilateral, small, palpable cervical lymph nodes, no ‘B’ symptoms or evidence of disease elsewhere; cervical lymph nodes with in situ mantle cell neoplasm<ref name=":0" /><ref name=":5">{{Cite journal|last=Aqel|first=N.|last2=Barker|first2=F.|last3=Patel|first3=K.|last4=Naresh|first4=K. N.|date=2008-01|title=In-situ mantle cell lymphoma--a report of two cases|url=https://pubmed.ncbi.nlm.nih.gov/18184277|journal=Histopathology|volume=52|issue=2|pages=256–260|doi=10.1111/j.1365-2559.2007.02906.x|issn=1365-2559|pmid=18184277}}</ref> | |||
|Overt mantle cell lymphoma (MCL) developed at 4 y<ref name=":0" /> | |||
|No | |||
|Cervical lymph nodes | |||
|- | |||
|N=1 | |||
|Male aged 65 y, in situ mantle cell neoplasm, retrospectively diagnosed in appendix excised for appendicitis<ref name=":0" /><ref name=":6">{{Cite journal|last=Bassarova|first=Assia|last2=Tierens|first2=Anne|last3=Lauritzsen|first3=Grete Fossum|last4=Fosså|first4=Alexander|last5=Delabie|first5=Jan|date=2008-10|title=Mantle cell lymphoma with partial involvement of the mantle zone: an early infiltration pattern of mantle cell lymphoma?|url=https://pubmed.ncbi.nlm.nih.gov/18696109|journal=Virchows Archiv: An International Journal of Pathology|volume=453|issue=4|pages=407–411|doi=10.1007/s00428-008-0621-x|issn=0945-6317|pmid=18696109}}</ref> | |||
|Overt MCL developed at 4 y<ref name=":0" /><ref name=":6" /> | |||
|No | |||
|Appendix in appendicitis | |||
|- | |||
|N=1 | |||
|Male aged 66 y, previously diagnosed MCL treated with chemotherapy and obtained complete remission; three years later, underwent prostatectomy for prostate cancer and the pelvic lymph nodes with that surgery were retrospectively examined later to reveal in situ mantle cell neoplasm<ref name=":0" /> | |||
|Overt relapsed MCL in inguinal lymph nodes at 1 y<ref name=":0" /> | |||
|No | |||
|Pelvic lymph nodes with prostatectomy for cancer | |||
|- | |||
| colspan="5" |'''28.5% (2 of 7) patients, both females, received chemotherapy''' | |||
|- | |||
|N=1 | |||
|Female aged 42 y, with multiple lymph node sites (axillary, cervical, inguinal, iliac) and gastrointestinal tract involved; in situ mantle cell neoplasm in enlarged lymph nodes; BM and PB not involved<ref name=":6" /> | |||
|Received chemotherapy; alive with no disease at 6 y<ref name=":6" /> | |||
|No | |||
|Axillary and inguinal lymph nodes and gastrointestinal tract biopsied | |||
|- | |||
|N=1 | |||
|Female aged 65 y, with in situ mantle cell neoplasm in enlarged lymph nodes, BM involved<ref name=":0" /> | |||
|Received chemotherapy; alive with no disease at 0.5 y<ref name=":0" /> | |||
|No | |||
|Lymph nodes, site not specified, with non-specific granulomas | |||
|- | |||
| colspan="5" |'''28.5% (2 of 7) patients, both males, given active surveillance until follow-up time''' | |||
|- | |||
|N=1 | |||
|Male aged 68 y, with in situ mantle cell neoplasm in enlarged mediastinal lymph nodes | |||
|Not treated | |||
Alive with no lymphoma at 1 y | |||
|No | |||
|Mediastinal lymph node | |||
|- | |||
|N=1 | |||
|Male aged 82 y, with previous chronic lymphocytic leukemia (CLL); in situ mantle cell neoplasm in enlarged oropharyngeal lymphoid tissue and peripheral blood involvement by MCL and CLL | |||
|Not treated | |||
Alive with disease at 3 y | |||
|Yes, with CLL | |||
|Oropharyngeal tissue | |||
|- | |||
! | |||
! colspan="4" |'''1 patient with in situ mantle cell neoplasm, SOX11 not performed'''<ref name=":0" /> | |||
|- | |||
|N=1 | |||
|Male aged 82 y, with CLL and in situ mantle cell neoplasm in an enlarged lymph node | |||
|Received chemotherapy; alive at 1.5 y | |||
|Yes, with CLL | |||
|Lymph node | |||
|- | |||
! colspan="5" |'''9 patients with in situ mantle cell neoplasm diagnosed with SOX11 negative neoplastic mantle cells<ref name=":0" />''' | |||
|- | |||
| colspan="3" |'''22% (2 of 9) patients, both females, with leukemic involvement of peripheral blood (PB) and bone marrow (BM) by MCL'''<ref name=":0" /> | |||
| | |||
| | |||
|- | |||
|N=1 | |||
|Female aged 29 y, with in situ mantle cell neoplasm in enlarged lymph nodes and leukemic involvement of peripheral blood and bone marrow<ref name=":0" /> | |||
|Active surveillance | |||
Leukemic involvement by MCL; alive with disease at 19.5 y<ref name=":0" /> | |||
|No | |||
|Axillary lymph node | |||
|- | |||
|N=1 | |||
|Female aged 70 y, presented in December 1999 with a slowly growing submandibular lymph node over 18 months; biopsy showed non-necrotizing granulomatous lymphadenitis with in situ mantle cell neoplasm; cytogenetics on lymph node tissue showed t(11;14)(q13;q32); PB and BM involved by leukemic mantle cells<ref name=":0" /><ref name=":4" /> | |||
|Active surveillance | |||
Leukemic involvement by MCL; alive with disease at 12 y<ref name=":0" /> | |||
|No | |||
|Submandibular lymph node with non-necrotizing granulomata | |||
|- | |||
| colspan="5" |'''33% patients (3 of 9), 2 males and 1 female, treated with chemotherapy or radiotherapy'''<ref name=":0" /> | |||
|- | |||
|N=1 | |||
|Male aged 42 y, with Castleman disease, hyaline vascular type<ref name=":0" /> | |||
|Treated with radiotherapy, alive at 1.7 y | |||
|No | |||
|Supraclavicular lymph node with Castleman disease, hyaline vascular type | |||
|- | |||
|N=1 | |||
|Male aged 58 y, clinical situation not known except for intestinal biopsy and bone marrow involved by neoplastic mantle cells<ref name=":0" /> | |||
|Treated with chemotherapy, alive at 1.4 y | |||
|No | |||
|Intestine | |||
|- | |||
|N=1 | |||
|Female aged 78 y with breast cancer treated by mastectomy 37 y prior to presentation with an enlarged posterior neck lymph node excised to show a composite lymphoma with in situ mantle cell neoplasm<ref name=":0" /><ref>{{Cite journal|last=Rodig|first=Scott J.|last2=Healey|first2=Barbara M.|last3=Pinkus|first3=Geraldine S.|last4=Kuo|first4=Frank C.|last5=Dal Cin|first5=Paola|last6=Kutok|first6=Jeffery L.|date=2006-11|title=Mantle cell lymphoma arising within primary nodal marginal zone lymphoma: a unique presentation of two uncommon B-cell lymphoproliferative disorders|url=https://pubmed.ncbi.nlm.nih.gov/17074590|journal=Cancer Genetics and Cytogenetics|volume=171|issue=1|pages=44–51|doi=10.1016/j.cancergencyto.2006.06.018|issn=0165-4608|pmid=17074590}}</ref> | |||
|Treated with radiotherapy, alive at 2 y | |||
|Yes, with nodal marginal zone lymphoma (MZL) | |||
|Posterior cervical lymph node | |||
|- | |||
| colspan="5" |'''Remaining 4 patients with SOX11 negative in situ mantle cell neoplasm'''<ref name=":0" /> | |||
|- | |||
|N=1 | |||
|Female aged 84 y with history of rectal carcinoma treated 5 y prior to splenectomy, which was performed due to multiple masses detected radiologically in the spleen; a composite lymphoma in the spleen with follicular lymphoma (FL), in situ follicular B-cell neoplasm and in situ mantle cell neoplasm <ref name=":9">{{Cite journal|last=Roullet|first=Michele R.|last2=Martinez|first2=Daniel|last3=Ma|first3=Lisa|last4=Fowler|first4=Melissa Halpern|last5=McPhail|first5=Ellen D.|last6=Judkins|first6=Alexander|last7=Arber|first7=Daniel A.|last8=Bagg|first8=Adam|date=2010-04|title=Coexisting follicular and mantle cell lymphoma with each having an in situ component: A novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/20231612|journal=American Journal of Clinical Pathology|volume=133|issue=4|pages=584–591|doi=10.1309/AJCP5RT4MRSDGKSX|issn=1943-7722|pmid=20231612}}</ref> | |||
|Refused treatment; intra-abdominal lymph nodes enlarged 9 months after splenectomy | |||
Dead at 13 months (1.1 y) of unknown cause<ref name=":9" /> | |||
|Yes, with FL and in situ follicular B-cell neoplasm<ref name=":9" /><ref name=":8" /> | |||
|Spleen | |||
|- | |||
|N=1 | |||
|Female aged 78 y, diagnosed with in situ mantle cell neoplasm in a composite lymphoma in an enlarged lacrimal gland with extranodal MZL and in situ mantle cell neoplasm<ref name=":0" /> | |||
|No follow-up available | |||
|Yes, with extranodal MZL | |||
|Lacrimal gland | |||
|- | |||
|N=1 | |||
|Male aged 59 y, with papillary thyroid cancer and in situ mantle cell neoplasm in cervical lymph nodes<ref name=":0" /> | |||
|Alive with no lymphoma at 5 y | |||
|No | |||
|Cervical lymph nodes with papillary thyroid carcinoma | |||
|- | |||
|N=1 | |||
|Female aged 42 y, with breast cancer and nodal involvement by in situ mantle cell neoplasm<ref name=":0" /> | |||
|Alive with no lymphoma at 1 y | |||
|No | |||
| | |||
|- | |||
! colspan="5" |Other reported patients with in situ mantle cell neoplasm | |||
|- | |||
|N=1 | |||
|Male aged 45 y, rectal biopsies due to bleeding per rectum diagnosed as benign colonic mucosa; Retrospective diagnosis of in situ mantle cell neoplasm made in the original rectal biopsy after overt MCL diagnosed 2 y later; after chemotherapy, residual lymphoid aggregates in colonic biopsies showed features similar to the original in situ mantle cell neoplasm with cyclin D1 positive and neoplastic cells positive for t(11;14) by FISH<ref>{{Cite journal|last=Neto|first=Antonio G.|last2=Oroszi|first2=Gabor|last3=Protiva|first3=Petr|last4=Rose|first4=Michal|last5=Shafi|first5=Nelofar|last6=Torres|first6=Richard|date=2012-12|title=Colonic in situ mantle cell lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/21840231|journal=Annals of Diagnostic Pathology|volume=16|issue=6|pages=508–514|doi=10.1016/j.anndiagpath.2011.05.001|issn=1532-8198|pmid=21840231}}</ref> | |||
|Overt, disseminated MCL at 2 y; at that time, patient presented with ileocecal intussusception due to enlarged lymph nodes | |||
|No | |||
|Rectal biopsy, original, and colonic biopsies after chemotherapy | |||
|- | |||
|N=1 | |||
|Female aged 71 y with overt MCL, clinical stage 4A, in 2013; retrospective review of previous lymph nodes excised with invasive ductal breast carcinoma in 2003 (ten y prior to the overt MCL) showed in situ mantle cell neoplasm<ref name=":3" /> | |||
|Overt MCL 10 y after in situ neoplasm; Dead 1 year after the diagnosis of overt MCL (or 11 y after diagnosis of in situ mantle cell neoplasm) | |||
|No | |||
|Lymph nodes excised with invasive ductal breast carcinoma; retrospective diagnosis | |||
|- | |||
|N=1 | |||
|Male aged 71 y, diagnosed with colonic adenocarcinoma with metastatic carcinoma in resected lymph nodes and retrospectively diagnosed in situ mantle cell neoplasm in a pericolonic lymph node 4 years later<ref>{{Cite journal|last=Edlefsen|first=Kerstin L.|last2=Greisman|first2=Harvey A.|last3=Yi|first3=Hye Son|last4=Mantei|first4=Kristin M.|last5=Fromm|first5=Jonathan R.|date=2011-08|title=Early lymph node involvement by mantle cell lymphoma limited to the germinal center: report of a case with a novel "follicular in situ" growth pattern|url=https://pubmed.ncbi.nlm.nih.gov/21757601|journal=American Journal of Clinical Pathology|volume=136|issue=2|pages=276–281|doi=10.1309/AJCP6KFFGTC8PLVR|issn=1943-7722|pmid=21757601}}</ref> | |||
|Overt MCL at 4 y diagnosed by biopsy of enlarged preauricular lymph node/parotid mass and BM; received chemotherapy; relapsed MCL 2 y post-chemotherapy | |||
|No | |||
|Pericolonic lymph node with metastatic colon adenocarcinoma | |||
|- | |||
|N=1 | |||
|Male aged 68 y, retrospective diagnosis of in situ mantle cell neoplasm in mesenteric lymph nodes resected with colorectal carcinoma; case identified in a systematic study as an incidental finding<ref name=":2" /> | |||
|Dead at 1.33 y (16 months), no lymphoma | |||
|No | |||
|Mesenteric lymph nodes with colorectal cancer; | |||
retrospective diagnosis | |||
|- | |||
|N=1 | |||
|Female aged 42 y, inguinal mass, imaging showed enlarged cervical, axillary, iliac, and inguinal lymph nodes, clinically staged as 4A; biopsy of inguinal and axillary lymph nodes showed a similar pattern in both lymph nodes of marked follicular hyperplasia and in situ mantle cell neoplasm<ref name=":6" /> | |||
|Chemotherapy given; further follow-up not available | |||
|No | |||
|Inguinal and axillary lymph nodes with lymphoid hyperplasia | |||
|- | |||
|N=1 | |||
|Female aged 46 y with breast cancer, retrospective diagnosis of in situ mantle cell neoplasm in axillary lymph nodes; case identified in a systematic study as an incidental finding<ref name=":2" /> | |||
|Alive at 16 y (192 months), no lymphoma | |||
|No | |||
|Axillary lymph nodes in breast cancer; retrospective diagnosis | |||
|- | |||
|N=1 | |||
|Male aged 79 y, overt MCL with clinical stage 1A in 2008, retrospective review of lymph nodes excised with malignant melanoma in 1988 (20 y prior to overt MCL) showed in situ mantle cell neoplasm<ref name=":3" /> | |||
|Overt MCL 20 y after in situ mantle cell neoplasm; Alive with lymphoma at the time of publication in 2015 (about 7 y from overt MCL) | |||
|No | |||
|Lymph nodes excised with malignant melanoma, retrospective | |||
|- | |||
|N=1 | |||
|Male with age in 40’s, with stage 4B follicular lymphoma (FL) diagnosed and treated 6 y before presentation with generalized lymphadenopathy at relapse; cervical lymph node at relapse showed a composite lymphoma composed of FL and in situ mantle cell neoplasm<ref name=":5" /> | |||
|No follow-up available | |||
|Yes, with FL | |||
|Cervical lymph node | |||
|- | |||
|N=1 | |||
|Female aged 76 y, clinical suspicion of lymphoma, previous history of right cheek squamous cell carcinoma; right cervical lymph node showed follicular lymphoma and in situ mantle cell neoplasm<ref name=":2" /> | |||
|Alive at 0.75 y (9 months), in remission | |||
|Yes, with FL | |||
|Right cervical lymph node with previous history of right cheek carcinoma | |||
|- | |||
|N=1 | |||
|Male aged 56 y, generalized lymphadenopathy, inguinal lymph node showed composite lymphoma (FL and in situ mantle cell lymphoma); cyclin D1 positive neoplastic mantle cells; | |||
Flow cytometric analysis of lymph node tissue showed the neoplastic mantle cells to express bright surface kappa light chain immunoglobulin while the FL cells expressed less bright kappa light chain immunoglobulin<ref>{{Cite journal|last=Demurtas|first=Anna|last2=Aliberti|first2=Sabrina|last3=Bonello|first3=Lisa|last4=Di Celle|first4=Paola Francia|last5=Cavaliere|first5=Cristina|last6=Barreca|first6=Antonella|last7=Novero|first7=Domenico|last8=Stacchini|first8=Alessandra|date=2011-04|title=Usefulness of multiparametric flow cytometry in detecting composite lymphoma: study of 17 cases in a 12-year period|url=https://pubmed.ncbi.nlm.nih.gov/21411776|journal=American Journal of Clinical Pathology|volume=135|issue=4|pages=541–555|doi=10.1309/AJCPQKE25ADCFZWN|issn=1943-7722|pmid=21411776}}</ref> | |||
|Received chemotherapy, in complete remission and alive at 27 months (2.25 y)<ref>{{Cite journal|last=Papathomas|first=Thomas G.|last2=Venizelos|first2=Ioannis|last3=Dunphy|first3=Cherie H.|last4=Said|first4=Jonathan W.|last5=Wang|first5=Michael L.|last6=Campo|first6=Elias|last7=Swerdlow|first7=Steven H.|last8=Chan|first8=John C.|last9=Bueso-Ramos|first9=Carlos E.|date=2012-04|title=Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications|url=https://pubmed.ncbi.nlm.nih.gov/22221705|journal=Human Pathology|volume=43|issue=4|pages=467–480|doi=10.1016/j.humpath.2011.08.024|issn=1532-8392|pmid=22221705}}</ref> | |||
|Yes, with FL | |||
|Inguinal lymph node biopsy | |||
|- | |||
|N=1 | |||
|Male aged 76 y, recent diagnosis of prostate carcinoma, with generalized lymphadenopathy, including in the axilla and mediastinum; axillary lymph node biopsy showed composite lymphoma with FL and in situ mantle cell neoplasm; BM and gastric biopsy involved by FL<ref>{{Cite journal|last=Subtil|first=Antonio|last2=Xu|first2=Zhaodong|date=2019-05-30|title=Follicular lymphoma with composite in situ mantle cell neoplasia|url=https://pubmed.ncbi.nlm.nih.gov/31147376|journal=Blood|volume=133|issue=22|pages=2460|doi=10.1182/blood.2019000012|issn=1528-0020|pmid=31147376}}</ref> | |||
|Not available | |||
|Yes, with FL | |||
|Axillary lymph node in a patient with recent diagnosis of prostate carcinoma | |||
|- | |||
|N=1 | |||
|Female aged 70 y, nasopharyngeal biopsy with lymphoid hyperplasia and situ mantle cell neoplasm; biopsy repeated at 3 y showed similar in situ mantle cell neoplasm<ref>{{Cite journal|last=Koletsa|first=Triantafyllia|last2=Markou|first2=Konstantinos|last3=Ouzounidou|first3=Sevasti|last4=Tsiompanou|first4=Fani|last5=Karkavelas|first5=Georgios|last6=Kostopoulos|first6=Ioannis|date=2013-11|title=In situ mantle cell lymphoma in the nasopharynx|url=https://pubmed.ncbi.nlm.nih.gov/23280758|journal=Head & Neck|volume=35|issue=11|pages=E333–337|doi=10.1002/hed.23206|issn=1097-0347|pmid=23280758}}</ref> | |||
|Alive with no progression to overt lymphoma at 3 y from first biopsy | |||
|No | |||
|Nasopharyngeal biopsy with lymphoid hyperplasia | |||
|- | |||
|N=1 | |||
|Female aged 31 y, cervical lymphadenopathy with Castleman disease, hyaline vascular type, with in situ mantle cell neoplasm<ref>{{Cite journal|last=Dobrea|first=Camelia|last2=Mihai|first2=Mihaela|last3=Dănăilă|first3=E.|last4=Găman|first4=Amelia|last5=Coriu|first5=D.|last6=Ursuleac|first6=Iulia|date=2011|title="In situ" mantle cell lymphoma associated with hyaline-vascular Castleman disease|url=https://pubmed.ncbi.nlm.nih.gov/22119840|journal=Romanian Journal of Morphology and Embryology = Revue Roumaine De Morphologie Et Embryologie|volume=52|issue=3 Suppl|pages=1147–1151|issn=2066-8279|pmid=22119840}}</ref> | |||
|Alive with no lymphoma at 0.66 y (8 months) | |||
|No | |||
|Cervical lymph node with Castleman disease, hyaline vascular type | |||
|- | |||
|N=1 | |||
|Male aged 73 y, lymphadenopathy with longstanding 20 y history of psoriasis; axillary lymph node showed dermatopathic lymphadenitis in conjunction with human herpes simplex virus 8 (HHV8) positive multicentric Castleman disease of mixed type and in situ mantle cell neoplasm<ref>{{Cite journal|last=Zanelli|first=Magda|last2=Stingeni|first2=Luca|last3=Zizzo|first3=Maurizio|last4=Martino|first4=Giovanni|last5=Sanguedolce|first5=Francesca|last6=Marra|first6=Andrea|last7=Crescenzi|first7=Barbara|last8=Pileri|first8=Stefano A.|last9=Ascani|first9=Stefano|date=2021-06-24|title=HHV8-Positive Castleman Disease and In Situ Mantle Cell Neoplasia within Dermatopathic Lymphadenitis, in Longstanding Psoriasis|url=https://pubmed.ncbi.nlm.nih.gov/34202434|journal=Diagnostics (Basel, Switzerland)|volume=11|issue=7|pages=1150|doi=10.3390/diagnostics11071150|issn=2075-4418|pmc=8305231|pmid=34202434}}</ref> | |||
|Treated with Rituximab followed by antibiotics for Staphylococcal infection at the time of publication in 2021 | |||
|No | |||
|Axillary lymph node with dermatopathic lymphadenitis and HHV8 positive multicentric Castleman disease | |||
|} | |||
The <u>sites of involvement</u> of this disease are detailed below: | |||
* Nodal and extranodal: virtually any lymphoid tissue sites in the body may be involved. | |||
* Bone marrow (BM) and peripheral blood (PB) may be involved by leukemic mantle cell lymphoma in patients with a histologic diagnosis of in situ mantle cell neoplasm in a lymph node or lymphoid tissue. In those cases, BM or PB involvement by neoplastic mantle cell lymphoma cells would be considered leukemic involvement (and not “in situ mantle cell neoplasm” in PB or BM). | |||
The <u>morphologic features</u> of this disease are detailed below: | |||
* In situ mantle cell neoplasm is characterized by the presence of cyclin D1 positive, SOX11 positive or negative, CD5 positive or negative, CD20 positive neoplastic B-cells in unexpanded mantle zones surrounding follicle centers in lymph nodes or extranodal lymphoid tissues. Rarely, the neoplastic mantle cells may also be present in the follicle center and identified only by immunohistochemical stains. The nodal architecture is preserved and is typically reactive-appearing except for the presence of the neoplastic in situ mantle cells that are identified by immunohistochemical staining for cyclin D1. The diagnosis can be difficult or may not even be possible to render solely by hematoxylin and eosin (H&E) stain morphology. | |||
* In situ mantle cell neoplasm must be differentiated from overt mantle cell lymphoma with a mantle zone pattern. In contrast with an in situ mantle cell neoplasm, overt mantle cell lymphoma may show any of the following features: greater follicle density than in a reactive lymph node, focal obliteration of nodal architecture, focally fused mantle zones, interfollicular neoplastic mantle cell nodules, and expanded mantle zones with monotonous or densely packed neoplastic mantle cells with slight to moderately irregular nuclear contours, slightly more open nuclear chromatin, inconspicuous nucleoli and scant cytoplasm. | |||
* Notably, in mantle cell lymphoma with a mantle zone pattern, the lymph node architecture may also be preserved, as reported.<ref name=":7">{{Cite journal|last=Richard|first=P.|last2=Vassallo|first2=J.|last3=Valmary|first3=S.|last4=Missoury|first4=R.|last5=Delsol|first5=G.|last6=Brousset|first6=P.|date=2006-09|title="In situ-like" mantle cell lymphoma: a report of two cases|url=https://pubmed.ncbi.nlm.nih.gov/16935977|journal=Journal of Clinical Pathology|volume=59|issue=9|pages=995–996|doi=10.1136/jcp.2005.030783|issn=0021-9746|pmc=1860464|pmid=16935977}}</ref> In those two cases, a high index of suspicion due to monotonous mantle cells with slight nuclear irregularity and the clinical history of lymphadenopathy at other sites led to a cyclin D1 stain and the accurate diagnosis of an overt mantle cell lymphoma.<ref name=":7" /> | |||
The <u>immunophenotype</u> of this disease is detailed below: | |||
* Immunohistochemistry for cyclin D1 is required for the diagnosis of in situ mantle cell neoplasm in virtually all cases. The neoplastic cells are CD20 positive B-cells that co-express cyclin D1. | |||
* Theoretically, cyclin D1 negative mantle cell lymphoma may also have an in situ neoplastic component but that has not yet been reported. | |||
Neoplastic cells Positive (universal) - CD20, cyclin D1 | |||
Neoplastic cells Positive (subset of cases) - CD5, SOX11 | |||
Neoplastic cells Negative (universal) - CD3 | |||
Neoplastic cells Negative (subset of cases) - CD5, SOX11 | |||
==Links== | ==Links== | ||
| Line 730: | Line 715: | ||
<nowiki>*</nowiki>''Citation of this Page'': “In situ mantle cell neoplasm”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:In_situ_mantle_cell_neoplasm</nowiki>. | <nowiki>*</nowiki>''Citation of this Page'': “In situ mantle cell neoplasm”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:In_situ_mantle_cell_neoplasm</nowiki>. | ||
[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases I]] | [[Category:HAEM5]] | ||
[[Category:DISEASE]] | |||
[[Category:Diseases I]] | |||